Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹1000 | ₹100 |
Expense Ratio | 1.88 | 1.36 |
NAV | ₹17.38 | ₹200.81 |
Fund Started | 11 Nov 2022 | 07 May 2007 |
Fund Size | ₹3538.38 Cr | ₹84854.73 Cr |
Exit Load | Exit load of 1% if redeemed within 1 year. | Exit load of 1% if redeemed within 1 year. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 3.70% | 6.10% |
3 Year | - | 25.05% |
5 Year | - | 28.68% |
1 Year
3 Year
5 Year
Equity | 96.28% | 93.60% |
Cash | 3.72% | 6.40% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Indian Bank | 2.60% |
Persistent Systems Ltd. | 2.58% |
One97 Communications Ltd. | 2.53% |
JK Cement Ltd. | 2.52% |
UNO Minda Ltd. | 2.33% |
HDFC Asset Management Company Ltd. | 2.32% |
Eternal Ltd. | 2.24% |
Dixon Technologies (India) Ltd. | 2.20% |
Max Financial Services Ltd. | 2.15% |
The Phoenix Mills Ltd. | 2.13% |
Name | Assets |
|---|---|
Max Financial Services Ltd. | 4.76% |
Balkrishna Industries Ltd. | 3.54% |
Indian Bank | 3.26% |
Fortis Healthcare Ltd. | 3.18% |
AU Small Finance Bank Ltd. | 3.16% |
Coforge Ltd. | 2.93% |
The Federal Bank Ltd. | 2.91% |
Hindustan Petroleum Corporation Ltd. | 2.90% |
Glenmark Pharmaceuticals Ltd. | 2.87% |
Ipca Laboratories Ltd. | 2.80% |
Name | Ajay Khandelwal | Chirag Setalvad |
Start Date | 25 Jul 2025 | 28 Jun 2014 |
Name
Start Date
Description | The Scheme seeks to generate capital appreciation by investing predominantly in equity and equity related instruments of mid cap companies. | The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies. |
Launch Date | 11 Nov 2022 | 07 May 2007 |
Description
Launch Date